Literature DB >> 22517416

Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding.

James Homans1, Shawna Christensen, Tracey Stiller, Chia-Hao Wang, Wendy Mack, Kathryn Anastos, Howard Minkoff, Mary Young, Ruth Greenblatt, Mardge Cohen, Howard Strickler, Roksana Karim, Lashonda Yvette Spencer, Eva Operskalski, Toinette Frederick, Andrea Kovacs.   

Abstract

BACKGROUND: Cervicovaginal HIV level (CV-VL) influences HIV transmission. Plasma viral load (PVL) correlates with CV-VL, but discordance is frequent. We evaluated how PVL, behavioral, immunological, and local factors/conditions individually and collectively correlate with CV-VL.
METHODS: CV-VL was measured in the cervicovaginal lavage fluid (CVL) of 481 HIV-infected women over 976 person-visits in a longitudinal cohort study. We correlated identified factors with CV-VL at individual person-visits and detectable/undetectable PVL strata by univariate and multivariate linear regression and with shedding pattern (never, intermittent, persistent ≥3 shedding visits) in 136 women with ≥3 visits by ordinal logistic regression.
RESULTS: Of 959 person-visits, 450 (46.9%) with available PVL were discordant, 435 (45.3%) had detectable PVL with undetectable CV-VL, and 15 (1.6%) had undetectable PVL with detectable CV-VL. Lower CV-VL correlated with highly active antiretroviral therapy (HAART) usage (P = 0.01). Higher CV-VL correlated with higher PVL (P < 0.001), inflammation-associated cellular changes (P = 0.03), cervical ectopy (P = 0.009), exudate (P = 0.005), and trichomoniasis (P = 0.03). In multivariate analysis of the PVL-detectable stratum, increased CV-VL correlated with the same factors and friability (P = 0.05), while with undetectable PVL, decreased CV-VL correlated with HAART use (P = 0.04). In longitudinal analysis, never (40.4%) and intermittent (44.9%) shedding were most frequent. Higher frequency shedders were more likely to have higher initial PVL [odds ratio (OR) = 2.47/log10 increase], herpes simplex virus type 2 seropositivity (OR = 3.21), and alcohol use (OR = 2.20).
CONCLUSIONS: Although PVL correlates strongly with CV-VL, discordance is frequent. When PVL is detectable, cervicovaginal inflammatory conditions correlate with increased shedding. However, genital shedding is sporadic and not reliably predicted by associated factors. HAART, by reducing PVL, is the most reliable means of reducing cervicovaginal shedding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22517416      PMCID: PMC3334315          DOI: 10.1097/QAI.0b013e31824aeaaa

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  42 in total

1.  Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding.

Authors:  Susan M Graham; Sarah E Holte; Norbert M Peshu; Barbra A Richardson; Dana D Panteleeff; Walter G Jaoko; Jeckoniah O Ndinya-Achola; Kishorchandra N Mandaliya; Julie M Overbaugh; R Scott McClelland
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

2.  Chronic alcohol consumption results in higher simian immunodeficiency virus replication in mucosally inoculated rhesus macaques.

Authors:  Bhawna Poonia; Steve Nelson; Greg J Bagby; Ping Zhang; Lee Quniton; Ronald S Veazey
Journal:  AIDS Res Hum Retroviruses       Date:  2006-06       Impact factor: 2.205

3.  Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis.

Authors:  Beverly E Sha; M Reza Zariffard; Qiong J Wang; Hua Y Chen; James Bremer; Mardge H Cohen; Gregory T Spear
Journal:  J Infect Dis       Date:  2004-12-02       Impact factor: 5.226

4.  Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months.

Authors:  Susan Cu-Uvin; Brad Snyder; Joseph I Harwell; Joseph Hogan; Carla Chibwesha; Dawn Hanley; Jessica Ingersoll; Jaclynn Kurpewski; Kenneth H Mayer; Angela M Caliendo
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

5.  Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy.

Authors:  Michael N Neely; Lorie Benning; Jiaao Xu; Howard D Strickler; Ruth M Greenblatt; Howard Minkoff; Mary Young; James Bremer; Alexandra M Levine; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2007-01-01       Impact factor: 3.731

6.  The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions.

Authors:  Arsenio Spinillo; Francesca Zara; Barbara Gardella; Eleonora Preti; Roberta Mainini; Renato Maserati
Journal:  Am J Obstet Gynecol       Date:  2005-03       Impact factor: 8.661

7.  Alcohol consumption and HIV-1 vaginal RNA shedding among women.

Authors:  Katherine P Theall; Angela Amedee; Rebecca A Clark; Jeanne Dumestre; Patricia Kissinger
Journal:  J Stud Alcohol Drugs       Date:  2008-05       Impact factor: 2.582

8.  Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

Authors:  Awewura Kwara; Allison Delong; Naser Rezk; Joseph Hogan; Heather Burtwell; Stacy Chapman; Carla C Moreira; Jaclyn Kurpewski; Jessica Ingersoll; Angela M Caliendo; Angela Kashuba; Susan Cu-Uvin
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

9.  Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women.

Authors:  Eva A Operskalski; Wendy J Mack; Howard D Strickler; Audrey L French; Michael Augenbraun; Phyllis C Tien; Maria C Villacres; LaShonda Y Spencer; Marina Degiacomo; Andrea Kovacs
Journal:  J Clin Virol       Date:  2008-02-20       Impact factor: 3.168

10.  Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes.

Authors:  Jérôme LeGoff; Helen A Weiss; Gérard Gresenguet; Khonde Nzambi; Eric Frost; Richard J Hayes; David C W Mabey; Jean-Elie Malkin; Philippe Mayaud; Laurent Belec
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

View more
  25 in total

Review 1.  Interventions to reduce alcohol use among HIV-infected individuals: a review and critique of the literature.

Authors:  Jennifer L Brown; Kelly S DeMartini; Jessica M Sales; Andrea L Swartzendruber; Ralph J DiClemente
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

2.  Alcohol Use and HIV Disease Progression in an Antiretroviral Naive Cohort.

Authors:  Judith A Hahn; Debbie M Cheng; Nneka I Emenyonu; Christine Lloyd-Travaglini; Robin Fatch; Starley B Shade; Christine Ngabirano; Julian Adong; Kendall Bryant; Winnie R Muyindike; Jeffrey H Samet
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-15       Impact factor: 3.731

3.  Characterization of the Genital Microenvironment of Female Rhesus Macaques Prior to and After SIV Infection.

Authors:  Whitney A Nichols; Leslie Birke; Jason Dufour; Nisha Loganantharaj; Gregory J Bagby; Steve Nelson; Patricia E Molina; Angela M Amedee
Journal:  Am J Reprod Immunol       Date:  2015-08-20       Impact factor: 3.886

4.  Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study.

Authors:  Sara Grignolo; Bianca Bruzzone; Laura Gabbi; Daniela Gerbaldo; Fabio Gallo; Nicola Nigro; Giancarlo Icardi; Claudio Viscoli; Antonio Di Biagio
Journal:  Virulence       Date:  2016-07-26       Impact factor: 5.882

5.  Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.

Authors:  Michael Neely; Stan Louie; Jiaao Xu; Patricia Anthony; Kasalyn Thuvamontolrat; Nicholas Mordwinkin; Andrea Kovacs
Journal:  J Clin Pharmacol       Date:  2015-03-30       Impact factor: 3.126

6.  Genital Shedding of Human Immunodeficiency Virus Type-1 (HIV) When Antiretroviral Therapy Suppresses HIV Replication in the Plasma.

Authors:  Marta Bull; Caroline Mitchell; Jaime Soria; Sheila Styrchak; Corey Williams; Joan Dragavon; Kevin J Ryan; Edward Acosta; Frankline Onchiri; Robert W Coombs; Alberto La Rosa; Eduardo Ticona; Lisa M Frenkel
Journal:  J Infect Dis       Date:  2020-08-04       Impact factor: 5.226

Review 7.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

8.  Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samples.

Authors:  Scott A Churchman; John A Moss; Marc M Baum
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-03-02       Impact factor: 3.205

9.  Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load.

Authors:  Kartik K Venkatesh; Allison K DeLong; Rami Kantor; Stacey Chapman; Jessica Ingersoll; Jaclynn Kurpewski; Maria Pia De Pasquale; Richard D'Aquila; Angela M Caliendo; Susan Cu-Uvin
Journal:  J Womens Health (Larchmt)       Date:  2013-03-26       Impact factor: 2.681

10.  Is there an association between HIV-1 genital shedding and cervical intraepithelial neoplasia 2/3 among women on antiretroviral therapy?

Authors:  Megan Justine Huchko; Victoria Woo; Teri Liegler; Anna Leddy; Karen Smith-McCune; George F Sawaya; Elizabeth A Bukusi; Craig R Cohen
Journal:  J Low Genit Tract Dis       Date:  2013-07       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.